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   Enhanced recovery pathways after surgery (ERAS) have 
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gained increased popularity within the last decade. The use 
of an ERAS protocol shorten hospital length of stay without 
compromising postoperative morbidity and mor- tality, even 
after complex surgical procedures like pan- 
creatoduodenectomy (PD) [1]. Evidence-based guidelines 
have provided a uniform platform for perioperative care for 
PD [2], addressing a large number of procedural items for 
the surgical pathway. Recent studies, investigating the effect 
of some of these items, have identified an improvement in 
clinical outcomes and a reduction in postoperative 
complications for patients with adherence to the ERAS 
protocol used [3, 4]. 
Abstract 
Background Evidence-based guidelines for enhanced recovery (ERAS) pathways after  pancreatoduodenectomy (PD) 
are available. Routine use of nasogatric tube (NGT) after PD is not recommended. This study aims to evaluate the 
need for NGT reinsertion after PD performed within an ERAS setting. 
Methods It is a prospective observational study of all patients undergoing PD in a tertiary referral hospital within the 
study period from 2015 throughout 2016. Pre- and postoperative variables were collected. Patients requiring NGT 
reinsertion were identified. Comparative analysis of patients with and without a NGT reinsertion was performed, as 
well as multivariate analysis for risk factors for on-demand NGT reinsertion. 
Results Two-hundred and one patients were included. In total, 45 (22.4%) patients required NGT reinsertion after 
PD. A total of 32 (15.9%) patients underwent a relaparotomy. Reinsertion of NGT in patients not undergoing a 
relaparotomy occurred in 26 (15.4%) patients. The presence of a major postoperative complication was a risk factor 
for reinsertion of NGT, OR 5.27 (2.54–10.94, p = 0.001). Patients with the need for a NGT reinsertion had a higher 
frequency of major postoperative complications and relaparotomy compared to patients without the need of a NGT 
reinsertion, 26 (57.8%) versus 32 (20.5%), p \ 0.001 and 19 (42.2%) versus 13 (8.3%), p \ 0.001, respectively. 
Conclusion Routine use of NGT after PD is not justified within an ERAS setting. Immediate removal of the NGT 




Some of the elements recommended by the ERAS 
guidelines have been notoriously difficult to implement. 
One of these is abolishing the routine use of nasogastric tube 
(NGT). This was documented to be safe after most  
abdominal operations a decade ago [5], but there were very 
limited data for PD patients at the time. The 2013 ERAS 
guidelines, however, strongly advised against preemptive 
use of nasogastric tubes postoperatively as it does not 
improve outcomes and may impede recovery [2]. Later 
studies have supported the recommendation of avoiding 
routine nasogastric decompression after pancreatic surgery 
[6–8]. These studies are limited, however, by small sample- 
size and often involve comparison with historical cohorts. 
Data on the effects of immediate removal of the NGT before 
endotracheal extubation in an ERAS setting are scarce. A 
selected adaptation of key elements from the 2012-
guidelines is often used in publications covering the 
implementation of ERAS in PD. However, while most local 
protocols dictate removal of the NGT on the day of surgery, 
the data on the actual removal of the tube reveals that this 
frequently occurs on postoperative day (POD) 1–3 or at the 
surgeons discretion, for various reasons [3, 4, 9]. Thus, an 
inherent resistance to immediate (intraoperatively before 
endotracheal extubation) removal of the NGT exists, even 
within an ERAS setting. The aim of this study was to 
evaluate the consequences of immediate NGT removal after 
PD in an enhanced recovery pathway and to assess the need 
for on-demand reinsertion. 
 
 
Materials and methods 
 
This is a prospective observational study of all consecutive 
patients undergoing PD at Oslo University Hospital, Rik- 
shospitalet, from January 2015 throughout December 2016. 
The hospital is a tertiary referral hospital and sole provider 
of major hepato-pancreato-biliary (HPB) surgery for 2.8 
million people within the South-Eastern Health Trust in 
Norway. Patients with other types of pancreatic resections 
were excluded. Hospital records with relevant pre- and 
postoperative variables were prospectively registered. The 
hospital review board approved the study according to the 
general guidelines provided by the regional ethics com-  
mittee. The manuscript was completed in accordance with 





All patients were preoperatively evaluated in a multidis- 
ciplinary meeting. Preoperative workup included a multi- 
detector computed tomography (CT) with an optimized 
pancreatic protocol and a chest CT. For patients with 
 
pancreatic ductal adenocarcinoma, both primary and bor- 
derline resectable pancreatic cancer, as defined by the 
NCCN criteria [11], were included in this cohort. Patients 
with borderline resectable disease were considered for four 
cycles of neoadjuvant chemotherapy, preferably FOLFIR- 
INOX before reevaluation of the disease and possible 
exploration and resection. A mid-line, upper transverse or 
reversed L-shaped incision was used according to sur- 
geon’s preference. A pylorus-preserving pancreatoduo- 
denectomy or a classic Whipple’s procedure with a standard 
lymphadenectomy was performed. In the case of suspicion 
of tumor involvement of mesenterico-portal vein axis, a 
resection of the involved vein was performed. Arterial 
resection was performed in highly selected patients. 
 
 




Dedicated  preoperative  counseling   was   performed   1–3 
weeks before surgery by a staff surgeon, anesthesiol- ogist 
and a trained nurse with specific knowledge of key elements 
of ERAS protocol. Preoperative biliary drainage was not 
performed routinely, but individually considered for   
patients   with   bilirubin   concentration C 250 lmol. 
Cessation  of  smoking  and  excessive  alcohol  intake was 
recommended for all patients. Dietary counseling was given 
routinely. Preoperative nutrition was not adminis- tered 
routinely. No bowel preparation was used. Patients were 
fasted for solid diet from midnight before surgery, but 
preoperative treatment with oral carbohydrate rich solu- 
tions was provided for all nondiabetic patients. Short-act- 
ing anxiolytics at the day of surgery were used according to 
patient preference. Low-molecular weight heparin (LMWH) 
at 100 Units/kg was administered the night before surgery, 
6 h after  surgery and continued daily  for  4 weeks after 
hospital discharge. Prior to skin incision, a mid-thoracic 
epidural was placed. Hypothermia during the procedure was 
prevented using a forced-air patient warm- ing system (3 
MTMBairHuggerTM, 3 M, USA). Peropera- tive intravenous 





The NGT was removed immediately after skin closure and 
before endotracheal extubation. Patient controlled analge- 
sia (PCA), wound catheters, transverse abdominal block or 
other intravenous analgesics were not used routinely. 
Administration of antiemetics during the day of the pro- 




hyperglycemia and near-zero fluid balance was strictly 
supervised during the initial postoperative period (POD 1–
3), and patients were discharged from the high-depen- dency 
unit to a step-down room (1 on 1 nursing facilities) in order 
to optimize this. A drain was placed underneath the 
hepaticojejunostomy and above the pancreaticoje- 
junostomy at the end of the procedure and early drain 
removal (POD 3) was warranted for all patients with nor- 
mal drain amylasis. Somastotain analogues were consid- 
ered standard of care throughout the study period (but have 
since then been abandoned). A transurethral catheter was 
inserted at the day of surgery and removed as soon as 
possible. Oral laxatives were not prescribed routinely, but 
according to patient performance. Early mobilization was 
initiated on the morning of POD 1, and patients were 
encouraged to meet daily targets for mobilization. There 
were no dietary restrictions after surgery, but patients were 
encouraged to begin carefully and increase intake accord- 
ing to tolerance over POD 1–4. Routine administration of 
artificial nutrition was not recommended but given 
according to surgeon’s preference. As a general rule, well- 
nourished patients not achieving adequate energy/protein 
requirement by oral intake within 5 days after the operation 
received artificial nutritional support. Malnourished patients 
and those who developed severe postoperative 
complications early after operation received early supple- 
mentary artificial nutrition. Patients were discharged to their 





The decision to reinsert the NGT in the postoperative course 
was based on surgeon’s preference according to clinical 
symptoms. For patients undergoing a relaparo- tomy, NGT 
reinsertion was routinely performed in order to facilitate 
gastric decompression. Provided patients were not sedated 
following a relaparotomy, NGTs were removed after 
surgery. Patients with reinserted NGT that remained during 
the following postoperative phase were registered as having 
a NGT reinsertion. Specific indications or symp- toms 
responsible for NGT reinsertion, as well as exact volume 





Severe   cardiac   disease   (NYHA   class   [2   or   severe 
arrhythmia) and pulmonary disease (FEV1 \ 50% and/or 
vital capacity \ 60%) were defined in concordance with 
the mE-PASS system [12]. Diabetes mellitus was consid- 
ered present if medically treated. Preoperative performance 
status was evaluated using the grading system provided by 
the Easter Cooperative Oncology Group [13]. Type of 
venous resection was classified as proposed by the ISGPS 
[14]. Complications were classified according to the 
accordion severity grading system [15].  Accordion  grade 
C 3 complications were registered and considered a major 
postoperative complication. Postpancreatectomy hemor- 
rhage, delayed gastric emptying (DGE) and clinically rel- 
evant pancreatic fistula were recorded according to the 
ISGPS-definitions [16–18]. Thirty- and 90-day mortality 
was assessed. Length of hospital stay was defined as the 
number of days after surgery until discharge home or to the 
local hospital. Days spent in local hospital following 




Descriptive statistics were used to summarize the data. 
Median (range) or mean (±standard deviation) values were 
used to express numerical data, where appropriate. Num- 
bers (percentages) were applied for categorical data. Two- 
sample Student’s t test and Man-Whitney U test were used 
to compare normally and not normally distributed numer- 
ical data, respectively. The Chi-square test or Fisher’s exact 
test was used to examine differences between the categorical 
variables. Two-tailed p \ 0.05 was considered statistically 
significant. 
Parameters that were significant in the univariable 
analysis were added to the multivariable logistic regression 
model to identify predictors for NGT reinsertion after PD. 
Two-tailed p \ 0.05 was considered statistically significant 





A total number of two-hundred and one patients underwent 
PD throughout the study period. Patient characteristics and 
intraoperative data are shown in Table 1. Ductal adeno- 
carcinoma was the most common indication for surgery 
(41.3%). Major postoperative complications, relaparotomy 
and 90-day mortality were observed in 28.9%, 15.9% and 
5.5% of patients, respectively (Table 2). DGE clinically 
grade B and C were observed in 18.4% and 12.8% of 
patients, respectively. 
Forty-five (22.4%) patients had a NGT reinsertion fol- 
lowing PD including 19 that eventually underwent rela- 
parotomy. Among those that did not undergo relaparotomy 
(169 patients), NGT was reinserted in 26 (15.4%) cases. In 
total, 19 (9.4%) patients without a major complication had 
reinsertion of a NGT (Table 2). The median time of NGT 
reinsertion after PD was POD 5. Female gender and younger 
age were significantly associated with a course without an 
NGT reinsertion, while intraoperative 
  
    
 
Table 1 Pre- and intraoperative characteristics of patients undergo- 
ing pancreatoduodenectomy 
  
Table 2 Postoperative outcomes in patients undergoing 
pancreatoduodenectomy 
 
Variables (n = 201)  Variables (n = 201) 
Age,  years, mean (SD) 67.1 (9.5)  Reinsertion of nasogastric tube, n (%) 45 (22.4%) 
Gender, n (%)  Reinsertion of NG tube in patients not undergoing a 
relaparotomy, n = 169 (%) 
26 (15.4%) 
Female 99 (49.3%) 
Male 102 (50.7%) 
Reinsertion of NG tube in patients not experiencing a 19 (9.4%) 














































parameters were comparable to those with NGT reinsertion 
(Table 3). The latter was associated with postoperative 
complications, grade B/C postoperative hemorrhage and 
In this study, we found that immediate removal of the NGT 
after PD could be accomplished without the need for 
subsequent reinsertion in the vast majority of the patients 
not experiencing a relaparotomy. Furthermore, the rates of 
major complications, relaparotomies and 90-day mortality 
after PD in our study are in line with those reported by others 
[19, 20], indicating that a routine of NGT on- 
  
BMI, kg/m2, mean (SD) 
24.5 (3.8) 
Days to reinsertion of nasogastric tube, median (range) 5 (1–42) 
Severe pulmonary disease, n (%) 
3 (1.5%) 
Days with reinserted nasogastric tube, median (range) 3.5 (1–21) 
Severe cardiac disease, n (%) 
11 (5.5%) 
Any use of parenteral nutrition after surgery, n (%) 98 (48.8%) 
Diabetes mellitus, n (%) 
36 (17.9%) 
Days from surgery to starting  parenteral nutrition, 4 (1–10) 
Neoadjuvant chemotherapy, n (%) 11 (5.5%) median (range)  
ECOG score  Major postoperative complications, n (%) 58 (28.9%) 
0 157 (78.1%) Postoperative hemorrhage (grade B/C), n (%) 24 (12%) 
1 39 (19.4%) Delayed gastric emptying, n (%)* 36 (18.4%) 
2 4 (2.0%) Grade A 11 (5.6%) 
3 and 4 1 (0.5%) Grade B 18 (9.2%) 
Peroperative biliary stent, n (%) 88 (43.8%) Grade C 7 (3.6%) 
ASA* score, n (%)  Clinically relevant pancreatic fistula (grade B/C) 21 (10.5%) 
1 3 (1.5%) 30-day mortality, n (%) 5 (2.5%) 
2 103 (51.5%) 90-day mortality, n (%) 11 (5.5%) 
3 and 4 94 (47%) Relaparotomy, n (%) 32 (15.9%) 
Serum albumin, mean (SD) 39.2 (4.8) Cause of relaparotomy, n (%)  
Tumor histology, n (%)  Hemorrhage 13 (6.5%) 
Pancreatic ductal adenocarcinoma 83 (41.3%) Pancreatic fistula 5 (2.5%) 
Common bile duct cancer 36 (17.9%) Biliary leakage 1 (0.5%) 
Duodenal cancer 24 (11.9%) Wound dehiscence 4 (2.0%) 
Ampullary cancer 9 (4.5%) Other 9 (4.4%) 
Other malignancy 20 (10%) Length of hospital stay, days, median (range) 7 (4–92) 
IPMN** 5 (2.5%) 
Chronic pancreatitis/other benign diseases 24 (12%) 
Type of procedure, n (%)    
Standard 63 (31.3%) relaparotomy. In the multivariable model, only male gen- 
Pylorus preserving 138 (68.7%) der and postoperative complications were independent 
Operative time, min, mean (SD) 353 (86) predictors for NGT reinsertion after PD (Table 4). For 
Estimated blood loss, ml, median (range) 200 (50–3700) patients without a major complication, the reinsertion rate 
Patients receiving red blood cell transfusion, n (%) 38 (18.9%) was significantly higher in older patients, mean (SD) 
Venous resection, n (%) 45 (22.4%) 71.4 years (6.4) versus 66.2 (10.6), p = 0.04 and patients 
Type 1 10 (5%) with an ECOG score C 1 (42.1% and 19.4%, p = 0.04), 
Type 2 3 (1.5%) data not shown. 
Type 3 26 (12.9%)  
Type 4 6 (3%)  





Table 3 Comparative analysis of patients with and without nasogastric tube reinsertion 
Variables NG-tube reinsertion (n = 45) No reinsertion (n = 156) p value 
Age, years, mean (SD) 69.4 (6.8) 66.4 (10.1) 0.023 
Gender, n (%)   0.006 
Female 14 (31.1%) 85 (54.5%)  
Male 31 (68.9%) 71 (45.5%)  
BMI, kg/m2, mean (SD) 25.4 (4.4) 24.3 (3.6) 0.61 
Severe pulmonary disease, n (%) 1 (2.2%) 2 (1.3%) 0.54 
Severe cardiac disease, n (%) 3 (6.7%) 8 (5.1%) 0.71 
Diabetes mellitus, n (%) 10 (22.2%) 26 (16.7%) 0.39 
Neoadjuvant chemotherapy, n (%) 1 (2.2%) 10 (6.4%) 0.46 
ECOG score   0.2 
0 32 (71.1%) 125 (80.1%)  
C 1 13 (28.9%) 31 (19.9%)  
Peroperative biliary stent, n (%) 17 (37.8%) 71 (45.5%) 0.4 
ASA score, n (%)   0.18 
½ 20 (44.4%) 87 (55.8%)  
¾ 25 (55.6%) 69 (44.2%)  
Serum albumin, mean (SD) 39.5 (4.6) 39.1 (4.9) 0.31 
Tumor histology, n (%)   0.38 
PDAC 16 (35.6%) 67 (42.9%)  
Other 29 (64.4%) 89 (57.1%)  
Type of procedure, n (%)   0.49 
Standard 16 (35.6%) 47 (30.1%)  
Pylorus preserving 29 (64.4%) 109 (69.9%)  
Operative time, min, mean (SD) 372 (81.1) 347 (86.3) 0.68 
Blood loss, ml, median (range) 350 (50–3100) 200 (50–3700) 0.07 
Red blood cell transfusion, n (%) 8 (18.2%) 30 (19.5%) 0.85 
Venous resection, n (%) 13 (28.9%) 32 (20.5%) 0.25 
Patch/Interposition graft 2 (15.4%) 7 (21.9%)  
Arterial resection, n (%) 4 (8.9%) 10 (6.4%) 0.52 
Major postoperative complications, n (%) 26 (57.8%) 32 (20.5%) \0.001 
Postoperative hemorrhage (grade B/C), n (%) 11 (24.4%) 13 (8.3%) 0.003 
Clinically relevant pancreatic fistula (grade B/C) 8 (17.8%) 13 (8.3%) 0.09 
Delayed gastric emptying, n (%)* 24 (55.8%) 12 (7.8%) \0.001 
Grade A 9 (20.9%) 2 (1.3%) \0.001 
Grade B/C 15 (34.9%) 10 (6.5%) \0.001 
Relaparotomy, n (%) 19 (42.2%) 13 (8.3%) \0.001 









Variables Odds  ratio (95% CI) p value 
 
demand-only in the immediate postoperative course after 
PD, does not compromise safety. 
The issue of NGT usage within an ERAS pathway 
   includes some key aspects. Firstly, the 2012 recommen- 
Age [65 years 1.80 (0.86–3.77)  0.192 
Gender (male) 2.80 (1.37–5.73) 0.008 
Major postoperative complications 5.27 (2.54–10.94) 0.001 
 
 
dations clearly advised that NGTs placed during surgery 
should be removed before reversal of anesthesia. Some 
recent reports show a surprising unwillingness to adhere to 
these recommendations, as the NGT is reported removed on 




[3, 4, 9, 21]. The reasons for this remain unclear, but sur- 
geons’ preference and the desire to monitor potential 
bleeding from the gastrojejunal anastomosis are reported. 
Secondly, even though previous publications support safe 
removal of NGT immediately after PD, the proportion that 
will subsequently require reinsertion of an NGT on demand 
remains unknown, even within an ERAS setting. High- 
lighting and identifying this subgroup of patients might 
elucidate reasons for reinsertion of NGT and evaluate 
potential causes for nonadherence to modern guidelines. In 
this study, approximately one out of five patients needed 
reinsertion of the NGT after PD. This number is in 
accordance with a recent publication investigating the 
outcomes of patients undergoing PD without nasogastric 
decompression [6]. The authors demonstrated that rein- 
sertion of NGT was required in 22.5% of patients who 
underwent a PD with immediate removal of the NGT after 
operation. The indications for reinsertion were secondary 
DGE due to postoperative complications. In our study 
population, the majority of patients undergoing a rela- 
parotomy had an NGT reinserted (19 of 32 patients). This 
leaves 26 (15.4%) patients with other reasons than rela- 
parotomy for reinsertion of NGT. This number is fairly low, 
indicating compliance with the 2013 ERAS guidelines 
[2] is possible and justified. 
The benefits of early parenteral nutrition after PD have 
been widely investigated. A review of different feeding 
routes after PD found no evidence to support either enteral 
or parenteral feeding compared to regular oral diet [22]. In 
this cohort, 48.8% of the patients were started on total 
parenteral nutrition (TPN) in the postoperative period. This 
is surprisingly high compared to a recent large cohort study 
on 1184 patients undergoing PD who found that a total of 
17.6% of the patients was given TPN in the postoperative 
period [23]. The median time of initiation of TPN was POD 
4 compared to POD 5 in our cohort. The most frequent 
reasons for initiation of TPN were delayed gastric empty- 
ing, pancreatic fistula and generalized malnutrition [23]. 
Although not recommended in a routine setting, TPN may 
be an important adjunct to aid in the recovery of patients 
who are unable to progress to an oral diet after PD, as 
suggested by others [23]. Nevertheless, the relatively high 
number of patients initiated on TPN in this study most likely 
indicates an overuse in some patients who would strictly not 
have needed this support. Also, the wide availability of 
dedicated clinical nutritionists for patients undergoing 
pancreatic surgery at our center may boost use of artificial 
nutritional support. Identifying patients who would benefit 
of TPN can be challenging. Adverse events like 
hyperglycemia and central line associated bloodstream 
infection are reported [23], which suggests that initiation of 
TPN needs careful justification. 
 
An important limitation of this study lies in its design. In-
depth analyses of reasons for NGT reinsertion and removal 
as well as TPN administration are not attempted as these 
decisions were according to surgeon’s preference, and 
further details were not recorded. It is a natural assumption 
that on-demand reinsertion of a NGT in a patient not 
experiencing a major complication or a rela- parotomy 
signals some degree of subjectively experienced DGE. As 
discussed above, we hesitate to interpret the rather high rate 
of parenteral nutrition use as an indication of the same. In 
spite of these limitations, this study adds support to the 
modern approach of immediate removal of NGTs after PD 
and shows that only a small proportion of uncomplicated 
cases will be in need of NGT reinsertion on demand within 
an enhanced recovery pathway. 
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